Intestinal MYC modulates obesity-related metabolic dysfunction

Yuhong Luo,Shoumei Yang,Xuan Wu,Shogo Takahashi,Lulu Sun,Jie Cai,Kristopher W. Krausz,Xiaozhen Guo,Henrique B. Dias,Oksana Gavrilova,Cen Xie,Changtao Jiang,Weiwei Liu,Frank J. Gonzalez

DOI: https://doi.org/10.1038/s42255-021-00421-8

IF: 19.865

2021-07-01

Nature Metabolism

Abstract:MYC is a transcription factor with broad biological functions, notably in the control of cell proliferation. Here, we show that intestinal MYC regulates systemic metabolism. We find that MYC expression is increased in ileum biopsies from individuals with obesity and positively correlates with body mass index. Intestine-specific reduction of MYC in mice improves high-fat-diet-induced obesity, insulin resistance, hepatic steatosis and steatohepatitis. Mechanistically, reduced expression of MYC in the intestine promotes glucagon-like peptide-1 (GLP-1) production and secretion. Moreover, we identify <i>Cers4</i>, encoding ceramide synthase 4, catalysing de novo ceramide synthesis, as a MYC target gene. Finally, we show that administration of the MYC inhibitor 10058-F4 has beneficial effects on high-fat-diet-induced metabolic disorders, and is accompanied by increased GLP-1 and reduced ceramide levels in serum. This study positions intestinal MYC as a putative drug target against metabolic diseases, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

endocrinology & metabolism

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the pathogenesis and potential therapeutic targets of non - alcoholic fatty liver disease (NAFLD) and its more severe stage, non - alcoholic steatohepatitis (NASH). Specifically, the research focuses on the function of the MYC gene in the intestine and explores its role in obesity - related metabolic disorders. By generating a mouse model with intestine - specific MYC deletion, the researchers aim to reveal how MYC regulates systemic metabolism and explore its potential as a drug target for the treatment of NAFLD and NASH. The study found that the expression of MYC was increased in ileal biopsy samples of obese individuals and was positively correlated with body mass index (BMI) and serum alanine aminotransferase (ALT) levels. In the mouse model, high - fat diet (HFD) - induced MYC overexpression exacerbated obesity and liver steatosis. Conversely, intestine - specific reduction of MYC expression could improve HFD - induced obesity, insulin resistance, liver steatosis and hepatitis. Mechanistically, the reduction of intestinal MYC promoted the production and secretion of glucagon - like peptide - 1 (GLP - 1) and inhibited the production and secretion of ceramide, which is an active lipid with multiple biological effects on insulin resistance, oxidative stress, endoplasmic reticulum stress, inflammation, energy metabolism and apoptosis. In addition, the study also found that Cers4 (encoding ceramide synthase 4, a key enzyme that catalyzes the de novo synthesis of ceramide) is a new target gene of MYC in the intestine. Pharmacological inhibition of MYC (using 10058 - F4) can improve diet - induced metabolic disorders, including obesity, liver steatosis and fibrosis. These results suggest that intestinal MYC may be a potential drug target for the treatment of metabolic diseases, including NAFLD and NASH.

Intestinal MYC modulates obesity-related metabolic dysfunction

Ire1 Alpha Rnase-Dependent Lipid Homeostasis Promotes Survival In Myc-Transformed Cancers

Endothelial c-Myc knockout disrupts metabolic homeostasis and triggers the development of obesity

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease

Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity

Intestinal stearoyl-coenzyme A desaturase-inhibition improves obesity-associated metabolic disorders

Myeloid PGC1β attenuates high-fat-diet induced inflammation via mitochondrial fission/mtDNA/Nlrp3 pathway

Enhanced Gastrointestinal Expression of Cytosolic Malic Enzyme (ME1) Induces Intestinal and Liver Lipogenic Gene Expression and Intestinal Cell Proliferation in Mice

SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long‐lived Myc hypomorphic mice

MYG1 drives glycolysis and colorectal cancer development through nuclear-mitochondrial collaboration

Role of Myc in Hepatocellular Proliferation and Hepatocarcinogenesis.

An Association between Decreased Small Intestinal RNA Modification and Disturbed Glucagon-like Peptide-1 Secretion under High-Fat Diet Stress

Targeting Myc-driven stress addiction in colorectal cancer

Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat

A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans

Obesity Modulates Intestinal Intraepithelial T Cell Persistence, CD103 and CCR9 Expression, and Outcome in Dextran Sulfate Sodium-Induced Colitis

Interaction between the gut microbiota and colonic enteroendocrine cells regulates host metabolism

Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models

Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feeding